drugset / Trial / NCT07007546

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants

NCT07007546

Phase 1 Completed 42 enrolled Abbisko Therapeutics Co, Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

To main objective is to evaluate the safety, tolerability, and pharmacokinetic profile of single or multiple oral doses of ABSK061 mini-tablets and to evaluate the effect of soft food with ABSK061 mini-tablets on its pharmacokinetic profile in healthy adult participants

Timeline

Start
2025-05-17
Primary completion
2025-07-30
Completion
2026-04-14

Drugs

EvaluationDrugModalityDoseRoute
Subject ABSK061 Unknown 1 mg Oral
Subject ABSK061 Unknown 5 mg Oral
Subject ABSK061 Unknown 10 mg Oral
Subject ABSK061 Unknown 35 mg Oral

Indications

No indication recorded.